Intercell gets $1 million from Merck for vaccine candidate Intercell, an Austrian biotechnology company, has received a $1 million milestone payment from Merck for progress in the development of a bacterial vaccine candidate. 09 Nov 2005 News
Odyssey of a bio database ends with UCB deal Oxford Genome licenses a genomic database with a long pedigree to Belgium’s UCB 26 Oct 2005 News
Oxford’s Avidex studies a new approach to diabetes Avidex is teaming up with diabetes specialists at King’s College London to work on a new approach to treating the Type I form of the disease. 12 Oct 2005 News